Skip to main content

Table 1 Sociodemographic and clinical characteristics of study participants

From: Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease

Variables

n = 160

Age (years) – mean ± SD

54.0 ± 11.2

Gender – n (%)

 Female

80 (50.0)

 Male

80 (50.0)

Race self-declaration – n (%)

 White

99 (61.9)

 Black

14 (8.8)

 Mulatto

37 (23.1)

 Other

10 (6.2)

Educational level – n (%)

 Elementary school incomplete

52 (32.5)

 Elementary school complete

26 (16.3)

 Secondary school

56 (35.1)

 College

21 (13.2)

 Postgraduate

5 (3.1)

Current employment status – n (%)

 Active

66 (41.3)

 Away due to PsA

33 (20.6)

 Retired due to PsA

20 (12.5)

 Retired or away for other reasons

31 (19.4)

 Unemployed

10 (6.3)

Classification of BMI – n (%)

 Eutrophic

35 (21.9)

 Overweight

70 (43.8)

 Obesity

55 (34.4)

Smoker – n (%)

24 (15.0)

Alcoholic – n (%)

19 (11.9)

Metabolic syndrome

100 (62.5)

Comorbidities

 Systemic Arterial Hypertension

82 (51.3)

 Diabetes Mellitus

34 (21.3)

 Dyslipidemia

106 (66.3)

 Depressive Disorder

31 (19.4)

 Fibromyalgia

28 (17.5)

Duration of cutaneous disease/psoriasis (years) - median (P25-P75)

18 (8-27)

Time of PsA symptoms (years) - median (P25-P75)

8 (5-14)

Type of psoriasis – n (%)

 Plaque

142 (88,8)

 Palm plantar

10(6,3)

 Others

8(5,1)

Onicopathy – n (%)

54 (33,8)

Current treatment – n (%)

 Biological

107 (66,9)

Joint count with edema - median (P25-P75)

1 (0-3)

Counting of joints with painful - median (P25-P75)

2 (0-5)

Enthesitis (SPARCC ≥1) – n (%)

33 (20.6)

Radiographic changed – n (%)

115 (71.9)

PASI≤1 – n (%)

66 (41.3)

Type of PsA involvment – n(%)

 Peripheral

109 (68,1)

 Axial

3 (1,9)

 Mixed

48 (30,0)

  1. SPARCC Spondyloarthritis Research Consortium of Canada Enthesitis Index. PASI Psoriasis Area Severity Index